Glioblastoma (GBM)
Conditions
Keywords
glioblastoma, suicidality, depression, observational
Brief summary
The aim of the study is to use standardized questionnaires to systematically record influencing factors or predictors for suicidal behavior in glioblastoma patients, particularly with regard to existing depression and anxiety symptoms.
Detailed description
Treatment will be provided in accordance with guidelines as part of the study. If a patient decides to participate in the study and have given consent, he/she will undergo a study visit. In addition to a consultation with a physician ("medical history"), this includes a physical examination and the completion of questionnaires (Patient Health Questionnaire-8 to assess depression, Generalized Anxiety Disorder-7 to assess anxiety, Scale of Suicidal Experiences and Behavior to assess suicidality, EORTC-QLQ-30, and EORTC-QLQ BN-20 to assess health-related quality of life, and a short questionnaire on social support for chronic illnesses). If a need for psycho-oncological treatment is identified during the consultation (or during the examination itself) or expressed by the patient, a referral to the relevant specialist department will be arranged (if this has not already been done). Patient data used in the study is taken from the medical record (master data, diagnosis, therapy, MRIs, etc.) and from the study visit.
Interventions
DIAGNOSTIC_TESTMedical history, physical examination, completing questionnaires, data collection
Medical history Physical examination Completion of validated questionnaires: * Suicide Scale (SSEV) * Patient Health Questionnaire-8 (PHQ-8) * Generalized Anxiety Disorder-7 (GAD-7) * EORTC-QLQ-30 * EORTC-QLQ-BN-20 * Short questionnaire on social support for chronic illnesses (SUCE-4) Data collection from medical records
Sponsors
University Hospital, Essen
University Hospital Muenster
Charite University, Berlin, Germany
University Hospital Heidelberg
Neurological Clinic, Knappschaftskrankenhaus Bochum-Langendreer, Bochum, Germany
Universitätsklinikum Hamburg-Eppendorf
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Newly diagnosed glioblastoma, IDH wild-type (CNS WHO classification of 2021) after finishing radiotherapy (before first recurrence) * Age ≥ 18 years
Exclusion criteria
* Participants with clinically significant aphasia or language barrier as assessed by the investigator * History of other malignant tumors * Known tumor predisposition syndrome (e.g., Li-Fraumeni syndrome, Cowden syndrome, etc.) * Recurrent glioblastoma
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Suicidality | in the last 4 weeks before participating in the study | Measured using a questionnaire |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Depression | in the last 2 weeks before participating in the study | Measured using a questionnaire |
| Anxiety | in the last 2 weeks before participating in the study | Measured using a questionnaire |
| Health-related quality of life (HRQoL) | in the last week before participating in the study | Measured using a questionnaire |
| Social support | at the time of participation in the study (current status queried) | Measured using a questionnaire |
Countries
Germany
Contacts
CONTACTChristoph Oster, Dr. med.
CONTACTMareike Rutenkröger, Dr. rer. medic.
PRINCIPAL_INVESTIGATORSied Kebir, PD Dr. med.
University Hospital, Essen
Outcome results
None listed